Coordination and Redox Dual-Responsive Mesoporous Organosilica Nanoparticles Amplify Immunogenic Cell Death for Cancer Chemoimmunotherapy.

Abstract

Amplifying the chemotherapy-driven immunogenic cell death (ICD) for efficient and safe cancer chemoimmunotherapy remains a challenge. Here, a potential ICD nanoamplifier containing diselenide-bridged mesoporous organosilica nanoparticles (MONs) and chemotherapeutic ruthenium compound (KP1339) to achieve cancer chemoimmunotherapy is tailored. KP1339-loaded MONs show controlled drug release profiles via glutathione (GSH)-responsive competitive coordination and matrix degradation. High concentration of MONs selectively evoked reactive oxygen species production, GSH depletion, and endoplasmic reticulum stress in cancer cells, thus amplifying the ICD of KP1339 and boosting robust antitumor immunological responses. After the combination of PD-L1 checkpoint blockade, cancer cell membrane-cloaked KP1339-loaded MONs not only regress primary tumor growth with low systemic toxicity, but also inhibit distant tumor growth and pulmonary metastasis of breast cancer. The results have shown the potential of coordination and redox dual-responsive MONs boosting amplified ICD for cancer chemoimmunotherapy.

• Authors: Fan Zhang, Fangman Chen, Chao Yang, Lei Wang, Hanze Hu, Xuezhao Li, Xiao Zheng, Zheng Wang, Zhimin Chang, Tianyu Li, Li Li, Mingfeng Ge, Jinzhi Du, Wen Sun, Wen-Fei Dong, Dan Shao
• Journal: Small (Weinheim an der Bergstrasse, Germany) (Small) Vol. 17 Issue 26 Pg. e2100006 (07 2021) ISSN: 1613-6829 [Electronic] Germany
• PMID: 34081391 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2021 Wiley-VCH GmbH.

Chemical References

• Drug Carriers
• Doxorubicin

Topics

• Cell Line, Tumor
• Doxorubicin
• Drug Carriers
• Drug Delivery Systems
• Humans
• Immunogenic Cell Death
• Nanoparticles
• Neoplasms (drug therapy)
• Oxidation-Reduction